MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Regeneron Pharmaceuticals Inc

Suletud

SektorTervishoid

599.49 1.95

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

582.49

Max

600.82

Põhinäitajad

By Trading Economics

Sissetulek

-423M

918M

Müük

69M

3.8B

P/E

Sektori keskmine

14.641

57.333

Aktsiakasum

12.07

Dividenditootlus

0.63

Kasumimarginaal

24.219

Töötajad

15,106

EBITDA

-534M

1.1B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+47.02% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.63%

2.63%

Järgmine tulemuste avaldamine

29. apr 2025

Turustatistika

By TradingEconomics

Turukapital

-13B

62B

Eelmine avamishind

597.54

Eelmine sulgemishind

599.49

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

Regeneron Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. veebr 2025, 12:13 UTC

Tulu

Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD

22. apr 2025, 10:51 UTC

Peamised uudised

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ

28. veebr 2025, 12:00 UTC

Peamised uudised

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4. veebr 2025, 11:58 UTC

Tulu

Regeneron 4Q Rev Up on Strong Sales of EYLEA HD

4. veebr 2025, 11:37 UTC

Tulu

Regeneron Pharma Sees 2025 Adjusted R&D $5B-$5.2B >REGN

4. veebr 2025, 11:37 UTC

Tulu

Regeneron Pharma Sees 2025 Gross Margin on Net Product Sales 87%-88% >REGN

4. veebr 2025, 11:36 UTC

Tulu

Regeneron Pharma Sees 2025 Capital Spending $850M-$975M >REGN

4. veebr 2025, 11:35 UTC

Tulu

Regeneron Pharma Declares Initial Quarterly Dividend of 88c >REGN

4. veebr 2025, 11:35 UTC

Tulu

Regeneron Pharma 4Q Adj EPS $12.07 >REGN

4. veebr 2025, 11:34 UTC

Tulu

Regeneron Pharma 4Q U.S. Net Sales for Eylea HD, Eylea Rose 2% to $1.5B >REGN

4. veebr 2025, 11:34 UTC

Tulu

Regeneron Pharma: 4Q Dupixent Global Net Sales Recorded by Sanofi Rose 15% to $3.7B >REGN

4. veebr 2025, 11:32 UTC

Tulu

Regeneron Pharma Board OKs Additional $3 Billion Share Repurchase >REGN

4. veebr 2025, 11:31 UTC

Tulu

Regeneron Pharma Initiates Quarterly Cash Dividend Program >REGN

31. jaan 2025, 08:30 UTC

Omandamised, ülevõtmised, äriostud

It's Bananas, but Stock Splits Can Pay Off. Here Are 5 Likely Contenders. -- Barrons.com

28. jaan 2025, 10:30 UTC

Peamised uudised

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

31. okt 2024, 13:58 UTC

Tulu

Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom -- IBD

31. okt 2024, 10:52 UTC

Tulu

Regeneron Earnings Top Views For Biotech Giant -- IBD

31. okt 2024, 10:34 UTC

Tulu

Regeneron Pharma 3Q Adj EPS $12.46 >REGN

31. okt 2024, 10:33 UTC

Tulu

Regeneron Pharma 3Q EPS Cut 43c by Acquired IPR&D Charge >REGN

31. okt 2024, 10:33 UTC

Tulu

Regeneron Pharma 3Q U.S. Sales for Eylea HD, Eylea Rose 3% to $1.54B >REGN

31. okt 2024, 10:32 UTC

Tulu

Regeneron Pharma: 3Q Dupixent Global Net Sales Recorded by Sanofi Rose 23% to $3.82B >REGN

31. okt 2024, 10:30 UTC

Tulu

Regeneron Pharma 3Q Rev $3.72B >REGN

31. okt 2024, 10:30 UTC

Tulu

Regeneron Pharma 3Q EPS $11.54 >REGN

31. okt 2024, 10:30 UTC

Tulu

Regeneron Pharma 3Q Net $1.34B >REGN

25. okt 2024, 20:25 UTC

Tulu

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

1. aug 2024, 11:50 UTC

Tulu

Regeneron Stock Climbs After Strong Second-Quarter Performance -- IBD

1. aug 2024, 10:37 UTC

Tulu

Regeneron Pharma 2Q Adj EPS $11.56 >REGN

1. aug 2024, 10:30 UTC

Tulu

Regeneron Pharma 2Q EPS $12.41 >REGN

1. aug 2024, 10:30 UTC

Tulu

Regeneron Pharma 2Q Net $1.43B >REGN

1. aug 2024, 10:30 UTC

Tulu

Regeneron Pharma 2Q Rev $3.55B >REGN

Võrdlus sarnastega

Hinnamuutus

Regeneron Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

47.02% tõus

12 kuu keskmine prognoos

Keskmine 881.75 USD  47.02%

Kõrge 1,120 USD

Madal 547 USD

Põhineb 21 Wall Streeti analüütiku instrumendi Regeneron Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

21 ratings

17

Osta

3

Hoia

1

Müü

Tehniline skoor

By Trading Central

554.18 / 603.77Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bullish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.